Zoetis Faces Steepest Test Yet as Pet-Care Weakness Forces Second Guidance Reset

Zoetis shares fall to near 52-week low after weak Q2 results and reduced full-year outlook, driven by soft US companion-animal demand and price-sensitive pet owners.

The pressure on Zoetis shows no sign of easing. Shares in the animal-health giant slid another 6.29 percent on Friday to EUR 62.84, bringing the stock within striking distance of its 52-week low after the company delivered a second consecutive quarter of disappointing results and slashed its full-year outlook.

The latest leg of the decline came just one day after the company published its second-quarter figures, which revealed a business grappling with a fundamental shift in pet-owner behavior. Revenue for the period came in at USD 2.5 billion, essentially flat year over year, with organic growth contracting by 1 percent. Net income totaled USD 691 million, or USD 1.65 per diluted share, while adjusted earnings reached USD 781 million, or USD 1.87 per share.

US Companion-Animal Business Bears the Brunt

The weakness was concentrated squarely in the company's home market. US revenue fell 7 percent to USD 1.3 billion, dragged down by an 11 percent slide in companion-animal products to USD 1.0 billion. The dermatology portfolio, a traditional stronghold, generated just USD 395 million as products like Simparica Trio faced increasingly price-sensitive consumers and intensifying competition. Meanwhile, Cerenia and Convenia have begun to feel the sting of generic rivals, and demand for Librela has softened.

CEO Kristin Peck attributed the shortfall to a "more pressured companion-animal market," pointing to fewer veterinary clinic visits and cost-conscious pet owners who are pulling back on discretionary treatments.

There were pockets of resilience, however. The US livestock business jumped 23 percent to USD 222 million, fueled by surging demand for Dectomax amid the ongoing screwworm outbreak. International operations also provided some cushion, growing 6 percent to USD 1.2 billion.

Guidance Cut Deepens as Wall Street Turns More Cautious

The second-quarter miss prompted management to take an ax to its full-year targets. Based on exchange rates as of July 21, Zoetis now expects revenue of USD 9.12 billion to USD 9.32 billion, implying organic growth of negative 3 percent to negative 1 percent. Adjusted net income is projected between USD 2.57 billion and USD 2.62 billion, an organic decline of 5 to 9 percent, while adjusted diluted earnings per share are seen at USD 6.15 to USD 6.25 — well below what the market had been anticipating.

The revised outlook triggered an immediate wave of target-price cuts from the sell side. JPMorgan trimmed its price objective from USD 130 to USD 115 while maintaining an "Overweight" rating — a move that served as the direct catalyst for Friday's sell-off. UBS went further, reducing its target from USD 85 to USD 80 with a neutral stance. William Blair also weighed in, downgrading the stock to "Market Perform" on Thursday, citing mounting pressure in core categories.

The pattern is by now familiar to shareholders. Late June saw TD Cowen slash its target from USD 150 to USD 104, still attached to a buy recommendation. The current analyst consensus reflects the deepening skepticism: seven buy ratings, nine holds, and one sell, with an average price target of USD 115.92 — a figure that sits comfortably above the current share price but does little to mask the near-term concerns.

Management Shake-Up Signals Strategic Reset

Amid the operational turbulence, Zoetis announced a significant reshuffling of its leadership. James "Jay" Saccaro, formerly of GE HealthCare, will assume the newly created dual role of Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, with oversight of global manufacturing added to his remit. The outgoing CFO, Wetteny Joseph, will transition into an advisory capacity alongside the CEO through early 2027 to ensure a smooth handover. In a parallel move, Abhay Nayak has been promoted to lead the commercial US business.

The management changes come as the company pushes forward with strategic initiatives despite the headwinds. Zoetis has accelerated the rollout of Lenivia and Portela in Canada and Europe following early approvals in the UK, where Portela — a novel antibody for pain management in cats — recently received the green light. The acquisition of teleradiology platform VitalRADS was completed about a month ago, and the planned purchase of Neogen's animal genomics business remains on track.

Legal Overhang and a Steep Year-to-Date Decline

Adding to the challenges is a class-action lawsuit pending in the US District Court for the Southern District of New York. The lead-plaintiff filing deadline passed in late July, with plaintiffs alleging that Zoetis and certain executives made misleading statements regarding growth, market share, and safety issues tied to Librela, Simparica Trio, Apoquel, and Cytopoint.

The stock's descent has been relentless. Friday's close left the shares just 0.87 percent above their 52-week low of EUR 62.30, and the year-to-date loss now stands at 41.47 percent. The May sell-off, when the stock plunged 21.5 percent following a weak first-quarter report, proved to be a harbinger of the volatility that has defined the past several months.

Despite the turmoil, the company has continued returning capital to shareholders, distributing USD 1.6 billion through dividends and buybacks since the start of the year. A quarterly dividend of USD 0.53 per share is scheduled for payment on September 1 to shareholders of record as of July 20.

For now, investors are left to weigh the company's operational progress against the deteriorating demand picture in its most important market — a balance that has tipped decisively against the stock in recent sessions.